Prior positive comments from patients in Neuralstem trial highlighted in report

theflyonthewall.com

In a report published January 25, WAMU 88.5 highlighted Neuralstem's (CUR) investigative work on using stem cells to treat spinal cord injuries, including previously published comments from patients in trials reporting some improvement. Shares of Neuralstem are up 1.6%, or 2c, to $1.28 in early trading.

View Comments (0)